US4714776A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antiallergic agents
Assignee: Riker Laboratories Inc
•
Filing: 1985-07-22
•
Granted: 1987-12-22
•
Expires: 2005-07-22
Abstract
Abstract Novel antiallergic agents are described which are carboxy-substituted 3,5-di(tertiary-butyl)-4-hydroxybenzophenones. Pharmaceutical compositions containing and pharmacological methods for using such compounds are also described, as are synthetic intermediates for preparing such compounds.
Inventors
- 👤 Randy L. Bell
- 👤 George G. I. Moore
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 00:51
CPC Classifications
C; C07; C07C; C07C255/00; A; A61; A61P; A61P37/00; A61P37/08; A61P43/00; C07C45/00; C07C45/45; C07C45/46; C07C49/00; C07C49/76; C07C49/82; C07C49/83; C07C49/84; C07C65/00; C07C65/32; C07C65/40
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
42 words
A compound of the formula ##STR20## wherein R is hydrogen, lower alkyl, lower alkoxy or chloro; or a derivative thereof selected from a lower alkyl ester, a (lower)alkylamino(lower)alkyl ester, a pharmaceutically acceptable (lower)alkylamino(lower)alkyl ester acid-addition salt and a pharmaceutically acceptable carboxylate salt.
Claim 2
Dependent Claim
42 words
A compound of the formula ##STR20## wherein R is hydrogen, lower alkyl, lower alkoxy or chloro; or a derivative thereof selected from a lower alkyl ester, a (lower)alkylamino(lower)alkyl ester, a pharmaceutically acceptable (lower)alkylamino(lower)alkyl ester acid-addition salt and a pharmaceutically acceptable carboxylate salt.
Claim 3
Dependent Claim
15 words
A compound according to claim 1, wherein the carboxyl is oriented para to the carbonyl.
Claim 4
Dependent Claim
16 words
A compound of the formula ##STR21## wherein R is hydrogen, lower alkyl, lower alkoxy or chloro.
Claim 5
Dependent Claim
16 words
A compound of the formula ##STR21## wherein R is hydrogen, lower alkyl, lower alkoxy or chloro.
Claim 6
Independent Claim
71 words
A method for inhibiting bronchoconstriction due to an allergic reaction in a mammal comprising administering a compound to said mammal in an amount effective to inhibit said bronchoconstriction, said compound being of the formula: ##STR22## wherein R is hydrogen, lower alkyl, lower alkoxy or chloro; or a derivative thereof selected from a lower alkyl ester, a (lower)alkylamino(lower)alkyl ester, a pharmaceutically acceptable (lower)alkylamino(lower)alkyl ester acid-addition salt and a pharmaceutically acceptable carboxylate salt.
Claim 7
Independent Claim
71 words
A method for inhibiting bronchoconstriction due to an allergic reaction in a mammal comprising administering a compound to said mammal in an amount effective to inhibit said bronchoconstriction, said compound being of the formula: ##STR22## wherein R is hydrogen, lower alkyl, lower alkoxy or chloro; or a derivative thereof selected from a lower alkyl ester, a (lower)alkylamino(lower)alkyl ester, a pharmaceutically acceptable (lower)alkylamino(lower)alkyl ester acid-addition salt and a pharmaceutically acceptable carboxylate salt.
Claim 8
Dependent Claim
70 words
An antiallergic pharmaceutical composition comprising an antiallergic compound and a pharmaceutically acceptable carrier, said antiallergic compound being present in an amount sufficient for providing an antiallergic response and being of the following formula: ##STR23## wherein R is hydrogen, lower alkyl, lower alkoxy or chloro; or a derivative thereof selected from a lower alkyl ester, a (lower)alkylamino(lower)alkyl ester, a pharmaceutically acceptable (lower)alkylamino(lower)alkyl ester acid-addition salt and a pharmaceutically acceptable carboxylate salt.
Claim 9
Dependent Claim
70 words
An antiallergic pharmaceutical composition comprising an antiallergic compound and a pharmaceutically acceptable carrier, said antiallergic compound being present in an amount sufficient for providing an antiallergic response and being of the following formula: ##STR23## wherein R is hydrogen, lower alkyl, lower alkoxy or chloro; or a derivative thereof selected from a lower alkyl ester, a (lower)alkylamino(lower)alkyl ester, a pharmaceutically acceptable (lower)alkylamino(lower)alkyl ester acid-addition salt and a pharmaceutically acceptable carboxylate salt.
Claim 10
Independent Claim
67 words
A method for inhibiting leukotriene synthesis in a mammal comprising administering a compound to said mammal in an amount effective to inhibit said synthesis, said compound being of the formula: ##STR24## wherein R is hydrogen, lower alkyl, lower alkoxy or chloro; or a derivative thereof selected from a lower alkyl ester, a (lower)alkylamino(lower)alkyl ester, a pharmaceutically acceptable (lower)alkylamino(lower)alkyl ester acid-addition salt and a pharmaceutically acceptable carboxylate salt.
Claim 11
Independent Claim
67 words
A method for inhibiting leukotriene synthesis in a mammal comprising administering a compound to said mammal in an amount effective to inhibit said synthesis, said compound being of the formula: ##STR24## wherein R is hydrogen, lower alkyl, lower alkoxy or chloro; or a derivative thereof selected from a lower alkyl ester, a (lower)alkylamino(lower)alkyl ester, a pharmaceutically acceptable (lower)alkylamino(lower)alkyl ester acid-addition salt and a pharmaceutically acceptable carboxylate salt.
Claim 12
Independent Claim
67 words
A method for inhibiting lipoxygenase activity in a mammal comprising administering a compound to said mammal in an amount effective to inhibit said activity, said compound being of the formula: ##STR25## wherein R is hydrogen, lower alkyl, lower alkoxy or chloro; or a derivative thereof selected from a lower alkyl ester, a (lower)alkylamino(lower)alkyl ester, a pharmaceutically acceptable (lower)alkylamino(lower)alkyl ester acid-addition salt and a pharmaceutically acceptable carboxylate salt.
Claim 13
Independent Claim
67 words
A method for inhibiting lipoxygenase activity in a mammal comprising administering a compound to said mammal in an amount effective to inhibit said activity, said compound being of the formula: ##STR25## wherein R is hydrogen, lower alkyl, lower alkoxy or chloro; or a derivative thereof selected from a lower alkyl ester, a (lower)alkylamino(lower)alkyl ester, a pharmaceutically acceptable (lower)alkylamino(lower)alkyl ester acid-addition salt and a pharmaceutically acceptable carboxylate salt.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-12-21 | 1991-06-22 | 1991-12-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-12-21 | 1995-06-22 | 1995-12-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-12-21 | 1999-06-22 | 1999-12-22 | $7700.00 | Window Closed / Lapsed |